<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32421156</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Use of Multimodal Imaging and Clinical Biomarkers in Presymptomatic Carriers of C9orf72 Repeat Expansion.</ArticleTitle><Pagination><StartPage>1008</StartPage><EndPage>1017</EndPage><MedlinePgn>1008-1017</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2020.1087</ELocationID><Abstract><AbstractText Label="IMPORTANCE">During a time with the potential for novel treatment strategies, early detection of disease manifestations at an individual level in presymptomatic carriers of a hexanucleotide repeat expansion in the C9orf72 gene (preSxC9) is becoming increasingly relevant.</AbstractText><AbstractText Label="OBJECTIVES">To evaluate changes in glucose metabolism before symptom onset of amyotrophic lateral sclerosis or frontotemporal dementia in preSxC9 using simultaneous fluorine 18-labeled fluorodeoxyglucose ([18F]FDG positron emission tomographic (PET) and magnetic resonance imaging as well as the mutation's association with clinical and fluid biomarkers.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">A prospective, case-control study enrolled 46 participants from November 30, 2015, until December 11, 2018. The study was conducted at the neuromuscular reference center of the University Hospitals Leuven, Leuven, Belgium.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Neuroimaging data were spatially normalized and analyzed at the voxel level at a height threshold of P&#x2009;&lt;&#x2009;.001, cluster-level familywise error-corrected threshold of P&#x2009;&lt;&#x2009;.05, and statistical significance was set at P&#x2009;&lt;&#x2009;.05 for the volume-of-interest level analysis, using Benjamini-Hochberg correction for multiple correction. W-score maps were computed using the individuals serving as controls as a reference to quantify the degree of [18F]FDG PET abnormality. The threshold for abnormality on the W-score maps was designated as an absolute W-score greater than or equal to 1.96. Neurofilament levels and performance on cognitive and neurologic examinations were determined. All hypothesis tests were 1-sided.</AbstractText><AbstractText Label="RESULTS">Of the 42 included participants, there were 17 with the preSxC9 mutation (12 women [71%]; mean [SD] age, 51 [9] years) and 25 healthy controls (12 women [48%]; mean [SD] age, 47 [10] years). Compared with control participants, significant clusters of relative hypometabolism were found in frontotemporal regions, basal ganglia, and thalami of preSxC9 participants and relative hypermetabolism in the peri-Rolandic region, superior frontal gyrus, and precuneus cortex. W-score frequency maps revealed reduced glucose metabolism with local maxima in the insular cortices, central opercular cortex, and thalami in up to 82% of preSxC9 participants and increased glucose metabolism in the precentral gyrus and precuneus cortex in up to 71% of preSxC9 participants. Other findings in the preSxC9 group were upper motor neuron involvement in 10 participants (59%), cognitive abnormalities in 5 participants (29%), and elevated neurofilament levels in 3 of 16 individuals (19%) who underwent lumbar puncture.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">The results suggest that [18F]FDG PET can identify glucose metabolic changes in preSxC9 at an individual level, preceding significantly elevated neurofilament levels and onset of symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Vocht</LastName><ForeName>Joke</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>KU Leuven, Department of Neurosciences, Experimental Neurology, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>KU Leuven, University Hospitals Leuven, University Psychiatric Center, Adult Psychiatry, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Hospitals Leuven, Department of Neurology, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VIB - Center of Brain &amp; Disease Research, Laboratory of Neurobiology, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blommaert</LastName><ForeName>Jeroen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>KU Leuven, Department of Oncology, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devrome</LastName><ForeName>Martijn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>KU Leuven, University Hospitals Leuven, Department of Imaging and Pathology, Division of Nuclear Medicine, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Radwan</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>KU Leuven, Department of Imaging and Pathology, Translational MRI, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Weehaeghe</LastName><ForeName>Donatienne</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>KU Leuven, University Hospitals Leuven, Department of Imaging and Pathology, Division of Nuclear Medicine, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Schaepdryver</LastName><ForeName>Maxim</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>KU Leuven, Department of Neurosciences, Laboratory for Molecular Neurobiomarker Research, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ceccarini</LastName><ForeName>Jenny</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>KU Leuven, University Hospitals Leuven, Department of Imaging and Pathology, Division of Nuclear Medicine, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rezaei</LastName><ForeName>Ahmadreza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>KU Leuven, University Hospitals Leuven, Department of Imaging and Pathology, Division of Nuclear Medicine, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schramm</LastName><ForeName>Georg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>KU Leuven, University Hospitals Leuven, Department of Imaging and Pathology, Division of Nuclear Medicine, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Aalst</LastName><ForeName>June</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>KU Leuven, University Hospitals Leuven, Department of Imaging and Pathology, Division of Nuclear Medicine, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chi&#xf2;</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ALS Center, Rita Levi Montalcini Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pagani</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Cognitive Sciences and Technologies, CNR, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stam</LastName><ForeName>Daphne</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>KU Leuven, Leuven Brain Institute, Laboratory for Translational Neuropsychiatry, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Esch</LastName><ForeName>Hilde</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>University Hospitals Leuven, Center for Human Genetics, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamaire</LastName><ForeName>Nikita</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>University Hospitals Leuven, Department of Neurology, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhaegen</LastName><ForeName>Marianne</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>KU Leuven, University Hospitals Leuven, University Psychiatric Center, Adult Psychiatry, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mertens</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>KU Leuven, University Hospitals Leuven, Department of Imaging and Pathology, Division of Nuclear Medicine, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poesen</LastName><ForeName>Koen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>KU Leuven, Department of Neurosciences, Laboratory for Molecular Neurobiomarker Research, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Leonard H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Brain Center Rudolf Magnus, Department of Neurology, University Medical Center Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Es</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Brain Center Rudolf Magnus, Department of Neurology, University Medical Center Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandenberghe</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>University Hospitals Leuven, Department of Neurology, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>KU Leuven, Department of Neurosciences, Laboratory for Cognitive Neurology, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandenbulcke</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>KU Leuven, Leuven Brain Institute, Laboratory for Translational Neuropsychiatry, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>KU Leuven, University Psychiatric Center, Geriatric Psychiatry, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van den Stock</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>KU Leuven, Leuven Brain Institute, Laboratory for Translational Neuropsychiatry, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>KU Leuven, University Psychiatric Center, Geriatric Psychiatry, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koole</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>KU Leuven, University Hospitals Leuven, Department of Imaging and Pathology, Division of Nuclear Medicine, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dupont</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>KU Leuven, Department of Neurosciences, Laboratory for Cognitive Neurology, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Laere</LastName><ForeName>Koen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>KU Leuven, University Hospitals Leuven, Department of Imaging and Pathology, Division of Nuclear Medicine, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>KU Leuven, Department of Neurosciences, Experimental Neurology, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Hospitals Leuven, Department of Neurology, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VIB - Center of Brain &amp; Disease Research, Laboratory of Neurobiology, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2021 Jan;20(1):15-17</RefSource><PMID Version="1">33340475</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064847" MajorTopicYN="N">Multimodal Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062706" MajorTopicYN="Y">Prodromal Symptoms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Ms De Vocht reported receiving grants from Universitair Ziekenhuis Leuven and the Thierry Latran Foundation during the conduct of the study. Dr Van Weehaeghe reported receiving grants from Fonds Wetenschappelijk onderzoek (FWO) during the conduct of the study. Dr Van Laere reported receiving grants from GE Healthcare, UCB, Janssens Pharmaceuticals, Eikonizo, Syndesi, and Cerveau outside the submitted work. Dr Van Damme reported receiving grants from the Thierry Latran Foundation during the conduct of the study; grants from E. von Behring Chair for Neuromuscular and Neurodegenerative Disorders, and payment to the institution from Alexion Pharmaceuticals, Pfizer, Cytokinetics, and Biogen for participation in advisory board meetings outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32421156</ArticleId><ArticleId IdType="pmc">PMC7417970</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2020.1087</ArticleId><ArticleId IdType="pii">2765969</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, et al. . Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17085. Published online October 20, 2017. doi:10.1038/nrdp.2017.71</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">29052611</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Hardiman O, Chio A, et al. . Amyotrophic lateral sclerosis. Lancet. 2017;390(10107):2084-2098. doi:10.1016/S0140-6736(17)31287-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162-172. doi:10.1056/NEJMra1603471</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Olney NT, Spina S, Miller BL. Frontotemporal dementia. Neurol Clin. 2017;35(2):339-374. doi:10.1016/j.ncl.2017.01.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2017.01.008</ArticleId><ArticleId IdType="pmc">PMC5472209</ArticleId><ArticleId IdType="pubmed">28410663</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, et al. ; ITALSGEN Consortium . A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21&#x2013;linked ALS-FTD. Neuron. 2011;72(2):257-268. doi:10.1016/j.neuron.2011.09.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. . Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p&#x2013;linked FTD and ALS. Neuron. 2011;72(2):245-256. doi:10.1016/j.neuron.2011.09.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Gijselinck I, Van Langenhove T, van der Zee J, et al. . A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol. 2012;11(1):54-65. doi:10.1016/S1474-4422(11)70261-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(11)70261-7</ArticleId><ArticleId IdType="pubmed">22154785</ArticleId></ArticleIdList></Reference><Reference><Citation>Mestre TA, Guttman M. The dawn of a new era for neurodegenerative disorders: Huntington&#x2019;s disease leading the way. Mov Disord. 2019;34(9):1301-1302. doi:10.1002/mds.27826</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.27826</ArticleId><ArticleId IdType="pubmed">31433876</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J. Presymptomatic studies in ALS: rationale, challenges, and approach. Neurology. 2012;79(16):1732-1739. doi:10.1212/WNL.0b013e31826e9b1d</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31826e9b1d</ArticleId><ArticleId IdType="pmc">PMC3468777</ArticleId><ArticleId IdType="pubmed">23071166</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Nicholas JM, Cash DM, et al. . Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurol. 2015;14(3):253-262. doi:10.1016/S1474-4422(14)70324-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70324-2</ArticleId><ArticleId IdType="pmc">PMC6742501</ArticleId><ArticleId IdType="pubmed">25662776</ArticleId></ArticleIdList></Reference><Reference><Citation>Tentolouris-Piperas V, Ryan NS, Thomas DL, Kinnunen KM. Brain imaging evidence of early involvement of subcortical regions in familial and sporadic Alzheimer&#x2019;s disease. Brain Res. 2017;1655:23-32. doi:10.1016/j.brainres.2016.11.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2016.11.011</ArticleId><ArticleId IdType="pubmed">27847196</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutsaerts HJMM, Mirza SS, Petr J, et al. ; GENetic Frontotemporal dementia Initiative (GENFI) . Cerebral perfusion changes in presymptomatic genetic frontotemporal dementia: a GENFI study. Brain. 2019;142(4):1108-1120. doi:10.1093/brain/awz039</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz039</ArticleId><ArticleId IdType="pmc">PMC6439322</ArticleId><ArticleId IdType="pubmed">30847466</ArticleId></ArticleIdList></Reference><Reference><Citation>Greaves CV, Rohrer JD. An update on genetic frontotemporal dementia. J Neurol. 2019;266(8):2075-2086. doi:10.1007/s00415-019-09363-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09363-4</ArticleId><ArticleId IdType="pmc">PMC6647117</ArticleId><ArticleId IdType="pubmed">31119452</ArticleId></ArticleIdList></Reference><Reference><Citation>Cash DM, Bocchetta M, Thomas DL, et al. ; Genetic FTD Initiative, GENFI . Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study. Neurobiol Aging. 2018;62:191-196. doi:10.1016/j.neurobiolaging.2017.10.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.10.008</ArticleId><ArticleId IdType="pmc">PMC5759893</ArticleId><ArticleId IdType="pubmed">29172163</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SE, Sias AC, Mandelli ML, et al. . Network degeneration and dysfunction in presymptomatic C9ORF72 expansion carriers. Neuroimage Clin. 2016;14:286-297. doi:10.1016/j.nicl.2016.12.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2016.12.006</ArticleId><ArticleId IdType="pmc">PMC5349617</ArticleId><ArticleId IdType="pubmed">28337409</ArticleId></ArticleIdList></Reference><Reference><Citation>Caverzasi E, Battistella G, Chu SA, et al. . Gyrification abnormalities in presymptomatic c9orf72 expansion carriers. J Neurol Neurosurg Psychiatry. 2019;90(9):1005-1010. doi:10.1136/jnnp-2018-320265</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-320265</ArticleId><ArticleId IdType="pmc">PMC6820159</ArticleId><ArticleId IdType="pubmed">31079065</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiskoot LC, Rombouts SARB, Panman JL, et al. . Neuropsychological and gray matter volume decline in presymptomatic C9Orf72 mutation carriers. Alzheimers Dement. 2016;12(7):62. doi:10.1016/j.jalz.2016.06.108</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.06.108</ArticleId></ArticleIdList></Reference><Reference><Citation>Rittman T, Borchert R, Jones S, et al. ; Genetic Frontotemporal Dementia Initiative (GENFI) . Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia. Neurobiol Aging. 2019;77:169-177. doi:10.1016/j.neurobiolaging.2018.12.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.12.009</ArticleId><ArticleId IdType="pmc">PMC6491498</ArticleId><ArticleId IdType="pubmed">30831384</ArticleId></ArticleIdList></Reference><Reference><Citation>Papma JM, Jiskoot LC, Panman JL, et al. . Cognition and gray and white matter characteristics of presymptomatic C9orf72 repeat expansion. Neurology. 2017;89(12):1256-1264. doi:10.1212/WNL.0000000000004393</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004393</ArticleId><ArticleId IdType="pubmed">28855404</ArticleId></ArticleIdList></Reference><Reference><Citation>Popuri K, Dowds E, Beg MF, et al. . Gray matter changes in asymptomatic C9orf72 and GRN mutation carriers. Neuroimage Clin. 2018;18(January):591-598. doi:10.1016/j.nicl.2018.02.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2018.02.017</ArticleId><ArticleId IdType="pmc">PMC5964622</ArticleId><ArticleId IdType="pubmed">29845007</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellami L, Bocchetta M, Masellis M, et al. ; Genetic FTD Initiative, GENFI . Distinct neuroanatomical correlates of neuropsychiatric symptoms in the three main forms of genetic frontotemporal dementia in the GENFI Cohort. J Alzheimers Dis. 2018;65(1):147-163. doi:10.3233/JAD-180053</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-180053</ArticleId><ArticleId IdType="pmc">PMC6087430</ArticleId><ArticleId IdType="pubmed">30010122</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K, Van Damme P. Diagnostic and prognostic performance of neurofilaments in ALS. Front Neurol. 2019;9:1167. doi:10.3389/fneur.2018.01167</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.01167</ArticleId><ArticleId IdType="pmc">PMC6345692</ArticleId><ArticleId IdType="pubmed">30713520</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeter LH, Dopper EG, Jiskoot LC, et al. . Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann Clin Transl Neurol. 2016;3(8):623-636. doi:10.1002/acn3.325</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.325</ArticleId><ArticleId IdType="pmc">PMC4999594</ArticleId><ArticleId IdType="pubmed">27606344</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol. 2018;84(1):130-139. doi:10.1002/ana.25276</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25276</ArticleId><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Lombardi V, et al. . Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(7-8):538-548. doi:10.1080/21678421.2019.1646769</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1646769</ArticleId><ArticleId IdType="pmc">PMC6768722</ArticleId><ArticleId IdType="pubmed">31432691</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Ende EL, Meeter LH, Poos JM, et al. ; Genetic Frontotemporal dementia Initiative (GENFI) . Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurol. 2019;18(12):1103-1111. doi:10.1016/S1474-4422(19)30354-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(19)30354-0</ArticleId><ArticleId IdType="pubmed">31701893</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeter LHH, Gendron TF, Sias AC, et al. . Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers. Ann Clin Transl Neurol. 2018;5(5):583-597. doi:10.1002/acn3.559</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.559</ArticleId><ArticleId IdType="pmc">PMC5945959</ArticleId><ArticleId IdType="pubmed">29761121</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Weehaeghe D, Ceccarini J, Delva A, Robberecht W, Van Damme P, Van Laere K. Prospective validation of 18F-FDG brain PET discriminant analysis methods in the diagnosis of amyotrophic lateral sclerosis. J Nucl Med. 2016;57(8):1238-1243. doi:10.2967/jnumed.115.166272</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.115.166272</ArticleId><ArticleId IdType="pubmed">26940764</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew S, Atassi N. Positron emission tomography molecular imaging biomarkers for amyotrophic lateral sclerosis. Front Neurol. 2019;10:135. doi:10.3389/fneur.2019.00135</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00135</ArticleId><ArticleId IdType="pmc">PMC6405430</ArticleId><ArticleId IdType="pubmed">30881332</ArticleId></ArticleIdList></Reference><Reference><Citation>Katisko K, Cajanus A, Korhonen T, Remes AM, Haapasalo A, Solje E. Prodromal and early bvFTD: evaluating clinical features and current biomarkers. Front Neurosci. 2019;13:658. doi:10.3389/fnins.2019.00658</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00658</ArticleId><ArticleId IdType="pmc">PMC6598427</ArticleId><ArticleId IdType="pubmed">31293376</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Laere K, Vanhee A, Verschueren J, et al. . Value of 18fluorodeoxyglucose&#x2013;positron-emission tomography in amyotrophic lateral sclerosis: a prospective study. JAMA Neurol. 2014;71(5):553-561. doi:10.1001/jamaneurol.2014.62</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.62</ArticleId><ArticleId IdType="pubmed">24615479</ArticleId></ArticleIdList></Reference><Reference><Citation>van Weehaeghe D, Ceccarini J, Willekens SM, de Vocht J, van Damme P, van Laere K. Is there a glucose metabolic signature of spreading TDP-43 pathology in amyotrophic lateral sclerosis? Q J Nucl Med Mol Imaging. 2020;64(1):96-104. doi:10.23736/S1824-4785.17.03009-6</Citation><ArticleIdList><ArticleId IdType="doi">10.23736/S1824-4785.17.03009-6</ArticleId><ArticleId IdType="pubmed">29166751</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Turner MR, Wuu J. Defining pre-symptomatic amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(5-6):303-309. doi:10.1080/21678421.2019.1587634</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1587634</ArticleId><ArticleId IdType="pmc">PMC6613999</ArticleId><ArticleId IdType="pubmed">30892087</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K, De Schaepdryver M, Stubendorff B, et al. . Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology. 2017;88(24):2302-2309. doi:10.1212/WNL.0000000000004029</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004029</ArticleId><ArticleId IdType="pubmed">28500227</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker LA, Schr&#xf6;der CD, Spreij LA, et al. . Derivation of norms for the Dutch version of the Edinburgh Cognitive and Behavioral ALS Screen. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(1-2):19-27. doi:10.1080/21678421.2018.1522352</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1522352</ArticleId><ArticleId IdType="pubmed">30314420</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, et al. . Amyotrophic lateral sclerosis&#x2014;frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(3-4):153-174. doi:10.1080/21678421.2016.1267768</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1267768</ArticleId><ArticleId IdType="pmc">PMC7409990</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrooten M, Smetcoren C, Robberecht W, Van Damme P. Benefit of the Awaji diagnostic algorithm for amyotrophic lateral sclerosis: a prospective study. Ann Neurol. 2011;70(1):79-83. doi:10.1002/ana.22380</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22380</ArticleId><ArticleId IdType="pubmed">21437935</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahams S, Newton J, Niven E, Foley J, Bak TH. Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(1-2):9-14. doi:10.3109/21678421.2013.805784</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.805784</ArticleId><ArticleId IdType="pubmed">23781974</ArticleId></ArticleIdList></Reference><Reference><Citation>Das SR, Avants BB, Grossman M, Gee JC. Registration based cortical thickness measurement. Neuroimage. 2009;45(3):867-879. doi:10.1016/j.neuroimage.2008.12.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2008.12.016</ArticleId><ArticleId IdType="pmc">PMC2836782</ArticleId><ArticleId IdType="pubmed">19150502</ArticleId></ArticleIdList></Reference><Reference><Citation>Wollenweber SD, Ambwani S, Delso G, et al. . Evaluation of an atlas-based PET head attenuation correction using PET/CT &amp; MR patient data. IEEE Trans Nucl Sci. 2013;60(5):3383-3390. doi:10.1109/TNS.2013.2273417</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/TNS.2013.2273417</ArticleId></ArticleIdList></Reference><Reference><Citation>Talairach J, Tournoux P. Co-Planar Stereotactic Atlas of the Human Brain. Thieme Medical Publishers; 1988.</Citation></Reference><Reference><Citation>Makris N, Goldstein JM, Kennedy D, et al. . Decreased volume of left and total anterior insular lobule in schizophrenia. Schizophr Res. 2006;83(2-3):155-171. doi:10.1016/j.schres.2005.11.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.schres.2005.11.020</ArticleId><ArticleId IdType="pubmed">16448806</ArticleId></ArticleIdList></Reference><Reference><Citation>Frazier JA, Chiu S, Breeze JL, et al. . Structural brain magnetic resonance imaging of limbic and thalamic volumes in pediatric bipolar disorder. Am J Psychiatry. 2005;162(7):1256-1265. doi:10.1176/appi.ajp.162.7.1256</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.162.7.1256</ArticleId><ArticleId IdType="pubmed">15994707</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, S&#xe9;gonne F, Fischl B, et al. . An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31(3):968-980. doi:10.1016/j.neuroimage.2006.01.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2006.01.021</ArticleId><ArticleId IdType="pubmed">16530430</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein JM, Seidman LJ, Makris N, et al. . Hypothalamic abnormalities in schizophrenia: sex effects and genetic vulnerability. Biol Psychiatry. 2007;61(8):935-945. doi:10.1016/j.biopsych.2006.06.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2006.06.027</ArticleId><ArticleId IdType="pubmed">17046727</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R, Perrotin A, Barr&#xe9; L, et al. . Region-specific hierarchy between atrophy, hypometabolism, and &#x3b2;-amyloid (A&#x3b2;) load in Alzheimer&#x2019;s disease dementia. J Neurosci. 2012;32(46):16265-16273. doi:10.1523/JNEUROSCI.2170-12.2012</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2170-12.2012</ArticleId><ArticleId IdType="pmc">PMC6794030</ArticleId><ArticleId IdType="pubmed">23152610</ArticleId></ArticleIdList></Reference><Reference><Citation>Bocchetta M, Cardoso MJ, Cash DM, Ourselin S, Warren JD, Rohrer JD. Patterns of regional cerebellar atrophy in genetic frontotemporal dementia. Neuroimage Clin. 2016;11:287-290. doi:10.1016/j.nicl.2016.02.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2016.02.008</ArticleId><ArticleId IdType="pmc">PMC4781923</ArticleId><ArticleId IdType="pubmed">26977398</ArticleId></ArticleIdList></Reference><Reference><Citation>Castelnovo V, Caminiti SP, Riva N, Magnani G, Silani V, Perani D. Heterogeneous brain FDG-PET metabolic patterns in patients with C9orf72 mutation. Neurol Sci. 2019;40(3):515-521. doi:10.1007/s10072-018-3685-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-018-3685-7</ArticleId><ArticleId IdType="pubmed">30554355</ArticleId></ArticleIdList></Reference><Reference><Citation>Diehl-Schmid J, Licata A, Goldhardt O, et al. ; FTLDc Study Group . FDG-PET underscores the key role of the thalamus in frontotemporal lobar degeneration caused by C9ORF72 mutations. Transl Psychiatry. 2019;9(1):54. doi:10.1038/s41398-019-0381-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-019-0381-1</ArticleId><ArticleId IdType="pmc">PMC6355852</ArticleId><ArticleId IdType="pubmed">30705258</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;necker S, Neuhofer C, Otto M, et al. ; Deutsches FTLD-Konsortium . Atrophy in the thalamus but not cerebellum is specific for C9orf72 FTD and ALS patients&#x2014;an atlas-based volumetric MRI study. Front Aging Neurosci. 2018;10(FEB):45. doi:10.3389/fnagi.2018.00045</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2018.00045</ArticleId><ArticleId IdType="pmc">PMC5863593</ArticleId><ArticleId IdType="pubmed">29599716</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeter LHH, Gendron TF, Sias AC, et al. . Poly-GP dipeptide repeats and neurofilament light chain as biomarkers in presymptomatic and symptomatic frontotemporal dementia caused by C9ORF72 repeat expansions. Alzheimers Dement. 2017;13(7):1228-1229. doi:10.1016/j.jalz.2017.07.425</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.07.425</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>